Τρίτη 3 Απριλίου 2018
Adding A New Analytical Procedure With Clinical Interpretation in the Tool Box of Survival Analysis
https://ift.tt/2JaHCQV
Cancers, Vol. 10, Pages 104: The Critical Role of Inflammation in the Pathogenesis and Progression of Myeloid Malignancies
Cancers, Vol. 10, Pages 104: The Critical Role of Inflammation in the Pathogenesis and Progression of Myeloid Malignancies
Cancers doi: 10.3390/cancers10040104
Authors: Brianna Craver Kenza El Alaoui Robyn Scherber Angela Fleischman
Hematopoietic stem cells (HSCs) maintain an organism's immune system for a lifetime, and derangements in HSC proliferation and differentiation result in hematologic malignancies. Chronic inflammation plays a contributory if not causal role in HSC dysfunction. Inflammation induces HSC exhaustion, which promotes the emergence of mutant clones that may be resistant to an inflammatory microenvironment; this likely promotes the onset of a myeloid hematologic malignancy. Inflammatory cytokines are characteristically high in patients with myeloid malignancies and are linked to disease initiation, symptom burden, disease progression, and worsened prognostic survival. This review will cover our current understanding of the role of inflammation in the initiation, progression, and complications of myeloid hematologic malignancies, drawing from clinical studies as well as murine models. We will also highlight inflammation as a therapeutic target in hematologic malignancies.
https://ift.tt/2H4bnlD
Appendiceal intussusception in the setting of ulcerative colitis
https://ift.tt/2Ip1632
Calcific tendonitis of the quadriceps tendon
https://ift.tt/2H32I2N
Pulmonary paraganglioma in a 10-year-old: a case report and review of the literature
https://ift.tt/2EftKRM
5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study

Source:European Journal of Cancer, Volume 95
Author(s): A. Ploquin, B. Pistilli, E. Tresch, J.S. Frenel, F. Lerebours, A. Lesur, C. Loustalot, T. Bachelot, M. Provansal, J.M. Ferrero, F. Coussy, M. Debled, P. Kerbrat, A. Vinceneux, D. Allouache, F. Morvan, F. Dalenc, S. Guiu, R. Rouzier, L. Vanlemmens
BackgroundBreast cancer diagnosed during pregnancy (BCP) is rare, but the prevalence is expected to rise. Long-term follow-up data regarding this clinically challenging condition are scarce. The main objective of this multicentre case-control French study was to compare the survival between pregnant patients and matched controls.MethodsPatients from 27 centres diagnosed between 2000 and 2009 with histologically proven invasive breast cancer occurring during pregnancy were retrospectively included. Controls were matched to BCP patients on age, clinical T stage, hormone receptor, HER2, administration of neo-adjuvant chemotherapy and pathological node involvement in the absence of neo-adjuvant chemotherapy. Five-year overall survival (OS), disease-free survival (DFS) and metastasis-free survival (MFS) rates were estimated using the Kaplan–Meier method.ResultsOne hundred and eleven BCP patients and 253 controls were included. Median age was 33 and 35 years, respectively. Both populations were managed similarly, except for less frequent sentinel node dissection (p = 0.026) and taxane administration (p = 0.03) among BCP patients. Median follow-up was 7.5 years. Survival rates were similar between both BCP and control patients: 5-year OS rates were 83.1% (95% CI: 74.5–89.0) vs 85.5% (95% CI: 80.4–89.4), respectively, p = 0.31; 5-year DFS rates 60.0% (95% CI: 50.1–68.6) vs 68.5% (95% CI: 62.3–73.9), respectively, p = 0.12 and 5-year MFS rates 71.0% (95% CI: 61.3–78.6) and 74.5% (95% CI: 68.6–79.5), respectively, p = 0.21.ConclusionOur study showed that the survival outcomes of patients diagnosed with BCP were not significantly different as compared to those of matched non-pregnant controls. A proper management of women diagnosed with BCP is crucial.
from Cancer via ola Kala on Inoreader https://ift.tt/2GxpT8k
via IFTTT